BSE filing, NSE: WELCURE. Summary written from the filing by ALFA Finder's alert engine.
Welcure Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹0.18
- Market cap
- ₹22.25 Cr
- Revenue (annual)
- ₹365.5 Cr
- Net profit (annual)
- ₹-5.49 Cr
- P/E (TTM)
- -1.3×Sector 45.9×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welcure Drugs & Pharmaceuticals Ltd
All →Welcure Drugs & Pharmaceuticals Board Meeting Outcome
Welcure Drugs & Pharmaceuticals approved the closure of its Ahmedabad corporate office. Operations will continue uninterrupted with records transferred to the registered office.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs submitted its Annual Secretarial Compliance Report for FY2026 under Regulation 24A. The report confirms overall compliance while noting historical fines paid for earlier procedural delays.
Welcure Drugs & Pharmaceuticals Q4 FY26 Results: Net Loss of ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Ltd reported a net loss of ₹49.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Financial Results
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
- Value
- ₹367.0 Cr
Welcure Drugs & Pharmaceuticals Board Meeting Date
Welcure Drugs scheduled a board meeting for May 29, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs & Pharmaceuticals Ltd submitted its Regulation 74(5) certificate for the quarter and year ended March 31, 2026. The registrar, Skyline Financial Services, confirmed that no physical share certificates were received for dematerialization during this period. This is a routine regulatory disclosure with no impact on business operations.
Other debt & borrowing announcements
All →Aptus Value Housing Finance India Debt & Borrowing: ₹0.89 Cr
Aptus Value Housing paid Rs.0.89 Crore monthly interest on its NCDs (ISIN INE852O07162) on 2 November 2026. The payment fulfils the scheduled coupon on Rs.150 Crore secured debentures.
- Value
- ₹0.89 Cr
HDB Financial Services Debt & Borrowing: ₹26.2 Cr
HDB Financial Services paid ₹26.20 Crore of interest on its Series 2024/18 subordinate bonds on 2 November 2026. This is routine servicing of existing debt obligations.
- Value
- ₹26.20 Cr
Moneyboxx Finance Debt & Borrowing: ₹0.06 Cr
Moneyboxx Finance paid ₹0.06 crore of monthly interest on its listed NCDs on October 31, 2026. The payment relates to ₹25 crore of secured debentures carrying 12% interest.
- Value
- ₹0.06 Cr
Magnum Ventures Debt & Borrowing: ₹1.65 Cr
Magnum Ventures paid Rs 1.65 Crore monthly NCD interest across two series on time. Payment was made October 26, 2026, ahead of the October 31 due date.
- Value
- ₹1.65 Cr
Sadhav Shipping Debt & Borrowing: ₹10 Cr
Sadhav Shipping approved a Rs. 10 crore term loan from Bajaj Finance Limited, secured against vessel AHTS Saroja Blessing. It carries 9.75% interest over 48 months.
- Value
- ₹10.00 Cr
- Execution
- 48 months, including a 3-month moratorium
Sakthi Finance Debt & Borrowing: ₹3.29 Cr
Sakthi Finance certified timely payment of ₹3.29 Crore monthly interest across 17 NCD tranches for October 2026. All payments were made on the due date.
- Value
- ₹3.29 Cr